BetterLife Pharma Inc. (BETR.CN)
CAD 0.09
(-10.53%)
CAD 0.09
(-10.53%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.19 Million CAD | 65.48% |
| 2022 | -9.24 Million CAD | 17.08% |
| 2021 | -9.95 Million CAD | -42.31% |
| 2020 | -7.83 Million CAD | -1.25% |
| 2019 | -17.4 Million CAD | -38.33% |
| 2018 | -6.88 Million CAD | -340.99% |
| 2017 | 47.36 Thousand CAD | 83.59% |
| 2016 | -8.16 Million CAD | 35.53% |
| 2015 | -11.99 Million CAD | -16688.74% |
| 2014 | -71.42 Thousand CAD | -57.31% |
| 2013 | -45.4 Thousand CAD | 49.12% |
| 2012 | 461.98 Thousand CAD | 75.11% |
| 2011 | 1.88 Million CAD | -113.09% |
| 2010 | -3.01 Million CAD | 2424.98% |
| 2009 | -117.79 Thousand CAD | 81.95% |
| 2008 | -652.7 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.26 Million CAD | 100.0% |
| 2024 Q2 | -1.11 Million CAD | 0.0% |
| 2023 Q3 | -156.58 Thousand CAD | 85.68% |
| 2023 Q2 | -1.09 Million CAD | -62.25% |
| 2023 Q1 | -673.84 Thousand CAD | 5.78% |
| 2023 Q4 | -730.25 Thousand CAD | -366.35% |
| 2023 FY | - CAD | 65.28% |
| 2022 Q4 | -715.21 Thousand CAD | 83.21% |
| 2022 Q1 | -3.04 Million CAD | -2.26% |
| 2022 Q2 | -1.35 Million CAD | 55.35% |
| 2022 Q3 | -4.25 Million CAD | -213.67% |
| 2022 FY | - CAD | 17.08% |
| 2021 Q2 | -3.59 Million CAD | -48.82% |
| 2021 FY | - CAD | -42.31% |
| 2021 Q1 | -2.41 Million CAD | 1.97% |
| 2021 Q3 | -2.15 Million CAD | 40.0% |
| 2021 Q4 | -2.97 Million CAD | -37.72% |
| 2020 Q2 | -1.37 Million CAD | -34.4% |
| 2020 Q1 | -1.02 Million CAD | -528.17% |
| 2020 Q4 | -2.46 Million CAD | 11.07% |
| 2020 FY | - CAD | -1.25% |
| 2020 Q3 | -2.77 Million CAD | -101.54% |
| 2019 FY | - CAD | -38.33% |
| 2019 Q1 | -1.4 Million CAD | -39.89% |
| 2019 Q4 | -163.01 Thousand CAD | 92.95% |
| 2019 Q3 | -2.31 Million CAD | 39.84% |
| 2019 Q2 | -3.84 Million CAD | -173.41% |
| 2018 Q2 | -1.44 Million CAD | 20.96% |
| 2018 Q1 | -1.82 Million CAD | -274.99% |
| 2018 Q4 | -1 Million CAD | 35.54% |
| 2018 Q3 | -1.55 Million CAD | -8.1% |
| 2018 FY | - CAD | -340.99% |
| 2017 Q1 | -293.9 Thousand CAD | 68.64% |
| 2017 FY | - CAD | 83.59% |
| 2017 Q4 | -486.72 Thousand CAD | -175.74% |
| 2017 Q3 | -176.51 Thousand CAD | 41.28% |
| 2017 Q2 | -300.59 Thousand CAD | -2.28% |
| 2016 Q2 | -1.37 Million CAD | 66.83% |
| 2016 Q3 | -844.7 Thousand CAD | 38.59% |
| 2016 FY | - CAD | 35.53% |
| 2016 Q4 | -937.13 Thousand CAD | -10.94% |
| 2016 Q1 | -4.14 Million CAD | 45.44% |
| 2015 Q4 | -7.6 Million CAD | -170330.72% |
| 2015 FY | - CAD | -16688.74% |
| 2015 Q2 | -2.94 Million CAD | -103.46% |
| 2015 Q1 | -1.44 Million CAD | -1996.42% |
| 2015 Q3 | -4460.00 CAD | 99.85% |
| 2014 Q2 | -29.72 Thousand CAD | 70.67% |
| 2014 Q1 | -101.34 Thousand CAD | -1113.68% |
| 2014 FY | - CAD | -57.31% |
| 2014 Q4 | 76.19 Thousand CAD | 560.56% |
| 2014 Q3 | -16.54 Thousand CAD | 44.35% |
| 2013 Q4 | 9998.00 CAD | 158.97% |
| 2013 Q2 | -27.19 Thousand CAD | -141.75% |
| 2013 Q3 | -16.95 Thousand CAD | 37.67% |
| 2013 Q1 | -11.25 Thousand CAD | -102.12% |
| 2013 FY | - CAD | 49.12% |
| 2012 Q4 | 530.17 Thousand CAD | 17872.14% |
| 2012 FY | - CAD | 75.11% |
| 2012 Q1 | -674.33 Thousand CAD | -123.55% |
| 2012 Q2 | 51.97 Thousand CAD | 107.71% |
| 2012 Q3 | 2950.00 CAD | -94.32% |
| 2011 Q1 | -2.46 Million CAD | -4607.51% |
| 2011 Q3 | -465.83 Thousand CAD | -60.51% |
| 2011 Q4 | 2.86 Million CAD | 714.66% |
| 2011 FY | - CAD | -113.09% |
| 2011 Q2 | -290.22 Thousand CAD | 88.25% |
| 2010 Q2 | -42.52 Thousand CAD | -57.19% |
| 2010 Q1 | -27.05 Thousand CAD | -68.16% |
| 2010 Q4 | -52.46 Thousand CAD | -159.92% |
| 2010 FY | - CAD | 2424.98% |
| 2010 Q3 | -20.18 Thousand CAD | 52.53% |
| 2009 Q2 | -75.96 Thousand CAD | -493.3% |
| 2009 Q3 | -14.11 Thousand CAD | 81.42% |
| 2009 FY | - CAD | 81.95% |
| 2009 Q4 | -16.08 Thousand CAD | -13.96% |
| 2009 Q1 | -12.8 Thousand CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -4.98 Million CAD | 35.933% |
| Asep Medical Holdings Inc | -8.13 Million CAD | 60.774% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 58.484% |
| ChitogenX Inc. | -2.69 Million CAD | -18.465% |
| Rapid Dose Therapeutics Corp. | -3.02 Million CAD | -5.512% |
| Defence Therapeutics Inc. | -12.67 Million CAD | 74.822% |
| Entheon Biomedical Corp. | 13.99 Thousand CAD | 22907.504% |
| Gemina Laboratories Ltd. | -5.17 Million CAD | 38.339% |
| Glow Lifetech Corp. | -1.26 Million CAD | -152.68% |
| Lexston Life Sciences Corp. | -648.32 Thousand CAD | -392.262% |
| Pharmala Biotech Holdings Inc. | -710.18 Thousand CAD | -349.383% |
| Doseology Sciences Inc. | -319.47 Thousand CAD | -898.959% |
| MYND Life Sciences Inc. | -1.82 Million CAD | -74.855% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | -165.446% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | -4.866% |
| PreveCeutical Medical Inc. | -955.08 Thousand CAD | -234.153% |
| Telescope Innovations Corp. | -5.49 Million CAD | 41.872% |